Hayes, Emily
Mewburn Ellis, LLP | Partner
In This Section
Emily handles patent work in the life sciences field with a focus on the biotechnology and pharmaceutical sectors.
Her expertise extends to:
protein, nucleic acid and antibody-based therapeutics and diagnostics
genomics and post-genomics research
gene manipulation
microbiology
vaccines
diagnostic and prognostic markers
Her practice focuses on drafting and prosecuting patent applications in these and related fields, as well as handling oppositions and appeals at the EPO. She also has a special interest in US patent law, having spent time on a secondment to a US firm in 2010.
Her clients include UK-based large and small biotechnology companies, universities and research charities. She also represents overseas clients, particularly US clients, at the European Patent Office, including multinational pharmaceutical companies, US biotech companies of all sizes, and US universities.
Emily has an M.Sci degree in Natural Sciences (Biochemistry) from the University of Cambridge and a Ph.D. in Biochemistry focussing on the development of an anti-angiogenic gene therapy for the treatment of cancer, also from the University of Cambridge.
Emily joined Mewburn Ellis LLP in 2005, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2009. She joined the partnership in 2013.
Her expertise extends to:
protein, nucleic acid and antibody-based therapeutics and diagnostics
genomics and post-genomics research
gene manipulation
microbiology
vaccines
diagnostic and prognostic markers
Her practice focuses on drafting and prosecuting patent applications in these and related fields, as well as handling oppositions and appeals at the EPO. She also has a special interest in US patent law, having spent time on a secondment to a US firm in 2010.
Her clients include UK-based large and small biotechnology companies, universities and research charities. She also represents overseas clients, particularly US clients, at the European Patent Office, including multinational pharmaceutical companies, US biotech companies of all sizes, and US universities.
Emily has an M.Sci degree in Natural Sciences (Biochemistry) from the University of Cambridge and a Ph.D. in Biochemistry focussing on the development of an anti-angiogenic gene therapy for the treatment of cancer, also from the University of Cambridge.
Emily joined Mewburn Ellis LLP in 2005, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2009. She joined the partnership in 2013.